WS12.3 May eosinophilic cystic fibrosis patients benefit from anti IL5-R monoclonal antibodies? Preliminary results of the MABCF cohort

Autor:	J. Moreau, M. Drevait, Boubou Camara, Sébastien Quétant, D. Caimi, S. Ramel, Raphaël Chiron, A. Coudrat, R. Chelabi
Rok vydání:	2020
Předmět:	Pulmonary and Respiratory Medicine Pathology medicine.medical_specialty medicine.drug_class business.industry Pediatrics Perinatology and Child Health Cohort Eosinophilic medicine Monoclonal antibody medicine.disease business Cystic fibrosis
Zdroj:	Journal of Cystic Fibrosis. 19:S20
ISSN:	1569-1993
DOI:	10.1016/s1569-1993(20)30229-0
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::7e46f282ae49ea70181c4a0a110dc862 https://doi.org/10.1016/s1569-1993(20)30229-0 Zobrazit plný text záznamu Full Text from ScienceDirect